3-37017602-A-G
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PP3PP5_Very_Strong
The NM_000249.4(MLH1):c.884+3A>G variant causes a splice region, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000249.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.884+3A>G intronic pathogenic mutation results from an A to G substitution 3 nucleotides after coding exon 10 in the MLH1 gene. This alteration has been reported in one family that met clinical criteria for Lynch syndrome, where the proband's tumor showed high microsatellite instability and the loss of MLH1 expression by immunohistochemistry (Terdiman JP et al. Gastroenterology. 2001 Jan;120:21-30). This variant was observed to segregate with colon and uterine cancer in several members of one family (Ambry internal data). In silico splice site analysis predicts that this alteration may weaken the native splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Other alterations impacting the same donor site have been shown to have a similar impact on splicing (van der Klift HM et al. Mol Genet Genomic Med. 2015 Jul;3:327-45; Casey G et al. JAMA. 2005 Feb;293:799-809; Rahner N et al. Acta Oncol. 2007;46:763-9; Tournier I et al. Hum. Mutat. 2008 Dec;29:1412-24; Thompson BA et al. Hum. Mutat. 2013 Jan;34:200-9; Soukarieh O et al. PLoS Genet. 2016 Jan;12:e1005756; Auclair J et al. Hum. Mutat. 2006 Feb;27:145-54; Spaepen M et al. Fam. Cancer. 2006;5:179-89). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence, this alteration is classified as a disease-causing mutation. -
This variant causes an A to G nucleotide substitution at the +3 position of intron 10 in the MLH1 gene. Functional RNA studies have shown that this variant causes an increase in skipping of exon 10 resulting in premature truncation of the MLH1 protein (PMID: 32133419). This variant has been reported in individuals affected with colorectal cancer (PMID: 11208710; ClinVar VariationID: 90413). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MLH1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. -
not provided Pathogenic:1Uncertain:1
The MLH1 c.884+3A>G variant was identified in 1 of 218 proband chromosomes (frequency: 0.005) from individuals or families with HNPCC (Terdiman 2001). The variant was also identified in dbSNP (ID: rs267607803) as “With Pathogenic allele”, ClinVar (classified as uncertain significance by InSight and Invitae; as likely pathogenic by Counsyl; and as pathogenic by Ambry Genetics), Mismatch Repair Genes Variant Database, and Insight Hereditary Tumors database (2x). The variant was not identified in GeneInsight-COGR, UMD-LSDB, or Zhejiang University databases. The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.884+3A>G variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. The variant occurs outside of the splicing consensus sequence and 4 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; however, this information is not predictive enough to assume pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -
The MLH1 c.884+3A>G variant has been reported in the published literature in individuals with Lynch syndrome related cancers (PMIDs: 11208710 (2001) and 36437392 (2023)). Functional studies demonstrated that this variant increases skipping of exon 10 (PMIDs: 31642931 (2019) and 32133419 (2020)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant may affect proper MLH1 mRNA splicing. Based on the available information, this variant is classified as likely pathogenic. -
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
- -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change falls in intron 10 of the MLH1 gene. It does not directly change the encoded amino acid sequence of the MLH1 protein. It affects a nucleotide within the consensus splice site. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with clinical features of Lynch syndrome (PMID: 11208710; external communication, internal data). It has also been observed to segregate with disease in related individuals. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MLH1 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,370,736 individuals referred to our laboratory for MLH1 testing. This variant is also known as IVS10+3A>G. ClinVar contains an entry for this variant (Variation ID: 90413). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at